Search Results
Inotuzumab Ozogamicin
Inotuzumab ozogamicin is FDA approved for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.
Olutasidenib
Olutasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Renewed focus on a national initiative to cure cancer
For more than 66 years The Leukemia & Lymphoma Society (LLS) has dedicated its energy and resources to finding cures for blood cancers, investing more than $1 billion over that time. Last night in his State of the Union address, President Obama appointed Vice President Joe Biden to take the lead in a “moon shot” mission to cure cancer. We at LLS agree the time is right.
“It’s personal for everybody,” the Vice President later said in a statement.
Is a Clinical Trial Right For You?
Because it can take up to 15 years for a new blood cancer drug to be studied and made available for doctors to prescribe, some patients opt for clinical trials as a way to gain early access to a promising treatment. Advancing new cancer therapies requires years of extensive clinical investigation, but clinical trials come with no guarantees. "A drug is allowed to enter the clinical trial phase based on scientific evidence including cell and animal studies, but it's still considered experimental and unproven.
NBA Rookie Honors Late Coach by Donating Car to LLS
Thanks to Karl-Anthony Towns, The Leukemia & Lymphoma Society (LLS) will be getting a brand new Kia!
The NBA awarded the 2015-16 Kia NBA Rookie of the Year Award to Karl-Anthony Towns of the Minnesota Timberwolves on May 16 by handing him keys to a brand new Sorento CUV.
“People Just Didn’t Get It”: Treating Young Adults with Cancer
Think of spring break: warm sunny skies, a refreshing drink, and hopefully, a feeling of freedom.
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
Methotrexate
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Omacetaxine mepesuccinate
Omacetaxine mepesuccinate is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
The effectiveness of omacetaxine mepesuccinate was evaluated using a combined group of patients whose cancer progressed after previous treatment with two or more TKIs. All participants were treated with omacetaxine mepesuccinate.
Avapritinib
Ayvakit® is indicated for the treatment of
Decitabine and cedazuridine
Inqovi is FDA approved for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Acalabrutinib
Acalabrutinib is a kinase inhibitor indicated for the treatment of adult patients with
- Mantle cell lymphoma (MCL) who have received at least one prior therapy
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
#ASH16 (Blog 3): Teaming Up to Beat AML
This is the third in a series of blogs covering the 58th ASH Annual Meeting and Exposition (#ASH16).
Because of You, We're Helping to Cure Cancer
Here at The Leukemia & Lymphoma Society (LLS), we remain laser-focused on continuing to drive forward our mission. In fact, we are amplifying our efforts to help patients and caregivers access the care they need, during the coronavirus crisis and beyond. Thankfully, we have a vibrant community of dedicated volunteers across the country who are just as relentless as we are about making a difference in the lives of blood cancer patients and their families.
Eight Years and Counting: "The Gray Zone"
If you want to get technical, I have cancer. At least I think I do. I was diagnosed eight years ago with chronic myeloid leukemia (CML) and while there are no longer any signs of disease in my bone marrow, this is a condition that never really goes away. The cancer-causing enzymes keep firing and my daily Gleevec pills continue pummeling them into submission. I like to think of myself as a cancer survivor, but dare I be so cocky? Not only do I not want to tempt fate, but it feels a bit like I’m staking claim to a territory I’m not fully entitled to.
Support at Your Fingertips: Try a Discussion Board
Having cancer can be a lonely experience, and it’s not always so easy to find others with a similar diagnosis. Even if you could, you might not always want to talk about everything face to face.
Sometimes an online discussion board is just what you need.
A phase 1 study of CB-012, a CRISPR-edited allogeneic CAR-T targeting CLL1, in patients with acute myeloid leukemia
In February 2021, LLS made an equity investment in Caribou Biosciences to "Support allogeneic CD371 (CLL-1) CAR development for acute myeloid leukemia." Caribou is a clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.Going to School on Cancer
This blog is the second in a series.
Alemtuzumab
Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).
Bosutinib
Bosutinib is FDA approved for the treatment of
- Adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.
- Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Filgrastim-sndz
Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:
- Patients with cancer receiving myelosuppressive chemotherapy;
- Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;
- Patients with cancer undergoing bone marrow transplantation;
- Patients undergoing autologous peripheral blood progenitor cell collection and therapy; and
- Patients with severe chronic neutropenia.
Hydroxyurea
Hydroxyurea is FDA approved to treat people who have chronic myelocytic leukemia and some other blood cancers, including essential thrombocythemia and polycythemia vera. Hydroxyurea may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Gemtuzumab ozogamicin
Gemtuzumab ozogamicin is approved for the treatment of
- Newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older
- Relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older (1.2).